29.15
1.01 (3.59%)
| Previous Close | 28.14 |
| Open | 28.33 |
| Volume | 578,338 |
| Avg. Volume (3M) | 703,778 |
| Market Cap | 1,898,236,288 |
| Price / Sales | 83.28 |
| Price / Book | 3.46 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -336.77% |
| Diluted EPS (TTM) | -3.11 |
| Quarterly Revenue Growth (YOY) | 114.80% |
| Total Debt/Equity (MRQ) | 10.98% |
| Current Ratio (MRQ) | 8.49 |
| Operating Cash Flow (TTM) | -234.06 M |
| Levered Free Cash Flow (TTM) | -136.32 M |
| Return on Assets (TTM) | -19.47% |
| Return on Equity (TTM) | -32.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Kymera Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 2.13 |
|
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.50% |
| % Held by Institutions | 104.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (RBC Capital, 140.14%) | Buy |
| Median | 56.50 (93.83%) | |
| Low | 53.00 (Wells Fargo, 81.82%) | Buy |
| 53.00 (Oppenheimer, 81.82%) | Buy | |
| Average | 59.00 (102.40%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 45.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 16 Sep 2025 | 70.00 (140.14%) | Buy | 47.28 |
| Oppenheimer | 27 Jun 2025 | 53.00 (81.82%) | Buy | 44.12 |
| HC Wainwright & Co. | 26 Jun 2025 | 60.00 (105.83%) | Buy | 45.71 |
| Wells Fargo | 26 Jun 2025 | 53.00 (81.82%) | Buy | 45.71 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary |
| 27 Aug 2025 | Announcement | Kymera Therapeutics to Participate in Upcoming September Investor Conferences |
| 11 Aug 2025 | Announcement | Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update |
| 04 Aug 2025 | Announcement | Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 |
| 26 Jun 2025 | Announcement | Kymera Therapeutics Announces Pricing of $250 Million Public Offering |
| 25 Jun 2025 | Announcement | Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update |
| 25 Jun 2025 | Announcement | Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders |
| 25 Jun 2025 | Announcement | Kymera Therapeutics Announces Proposed Public Offering |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |